目的：对晚期食管癌治疗中奈达铂(NDP)联合氟尿嘧啶(5-Fu)的临床治疗效果进行观察与有效性探讨。方法选取2013年11月—2015年11月从新疆生产建设兵团第六师医院收治的初治、Ⅲ~Ⅳ期晚期食管癌、无手术指征、体能状态评分为0~2分、预计生存期≥3个月的病例中随机选取患者共46例，其中男24例，女22例。采用随机数字表法将患者随机分为对照组与实验组，每组患者23例。其中对照组采用顺铂(DDP)联合5-Fu治疗，实验组采用NDP联合5-Fu治疗。按照RECIST标准和WHO不良反应分级标准，评价疗效及不良反应。利用SPSS 17.0统计学软件对两组患者的临床效果与不良反应进行对比性分析。结果经过3个月时间的治疗，实验组患者的DCR为95.6%，而对照组患者的DCR为73.9%，实验组患者的 RR为78.3%，对照组患者的RR为39.1%，实验组患者的不良反应发生率为26.0%，而对照组患者的不良反应发生率为69.6%，两组研究结果分析表明差异有统计学意义(P<0.05)。结论奈达铂联合氟尿嘧啶治疗食管癌临床效果显著，不良反应发生率较低，极大程度上避免了剧烈血液学毒性及胃肠道反应的发生。%Objective To observe the efficacy and safety of chemotherapy regimens nedaplatin combined with 5-FU. Methods A total of 46 newly-diagnosed from Derember 2013 to December 2015, stage Ⅲc/Ⅳ advanced esophagus cancer patients (no surgical indication, ECOG performance scores 0-2 and expected survival time ≥3 months) were recruited from Xinjiang production and Construction Corps Sixth Division Hospital. The number of male patients was 24 and female was 22. The patients were randomly divided into two groups. One was study group in which the patients received NDP plus 5-Fu regimen. The other was control group received DDP plus 5-Fu regimen. Each group had 23 patients and each patient went through 3 months treatment. According to RECIST Standard and WHO ADR (adverse drug reaction) grading system, we evaluated the curative effect weight changes. Apply SPSS 17.0 software to analyze the comparison between two groups. Results After 3 months treatment, DCR of study group is 95.6% and control group is 73.9%, RR of study group is 78.3%and control group is 39.1%, ADR of study group is 26.0%and control group is 69.6%. Conclusion NDP plus 5-Fu regimen in the treatment of esophagus cancer, can reduce ADRs and on the other hand can improve clinical symptoms. In summary, it had significant value in clinical application and research.
展开▼
